

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2025/128551 A9

(43) International Publication Date
19 June 2025 (19.06.2025)

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/18 (2006.01)
C07K 16/44 (2006.01) C12N 15/864 (2006.01)

ter Hall, Gainesville, FL 32611 (US). **THE CHILDREN'S HOSPITAL OF PHILADELPHIA** [US/US]; 3401 Civic Center Boulevard, Philadelphia, PA 19104 (US).

(21) International Application Number:

PCT/US2024/059352

(72) Inventor; and

(71) Applicant: **RANUM, Laura** [US/US]; 223 Grinter Hall, Gainesville, FL 32611 (US).

(22) International Filing Date:

10 December 2024 (10.12.2024)

(72) Inventors: **ROMANO, Lisa**; 223 Grinter Hall, Gainesville, FL 32611 (US). **DAVIDSON, Beverly, L.**; 3401 Civic Center Boulevard, Philadelphia, PA 19104 (US).

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/608,667 11 December 2023 (11.12.2023) US
63/554,852 16 February 2024 (16.02.2024) US
63/645,222 10 May 2024 (10.05.2024) US

(74) Agent: **MACDONALD, Kevin** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

(71) Applicants: **UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED** [US/US]; 223 Grinter

(54) Title: AAV-BASED ANTI-GA THERAPY




FIG. 2

(57) Abstract: Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as amyotrophic lateral sclerosis (ALS). In some embodiments, the disclosure relates to recombinant adeno-associated viruses (rAAVs) expressing antibodies and antigen-binding fragments thereof that bind to poly(GA) RAN proteins. In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof the rAAVs.

[Continued on next page]

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (*Art. 21(3)*)
- with sequence listing part of description (*Rule 5.2(a)*)

(48) Date of publication of this corrected version:

10 July 2025 (10.07.2025)

(15) Information about Correction:

see Notice of 10 July 2025 (10.07.2025)